Original Wu Yue Minenet
Highlights
Recently, Chengdu Beite Pharmaceutical's iodophorol injection was approved for marketing, becoming the company's sixth contrast agent. In 2023, at the end of China's public hospitals, iodophorol injection is the TOP1 product of contrast agent, with sales exceeding 3 billion yuan. At present, the company still has 4 new contrast agent products under review, attacking the 10 billion market.
Figure 1: Chengdu Beite Pharmaceutical's latest approved products
Source: NMPA official website
Iodophorol injection is a non-ionic, hypoosmotic, water-soluble, radiopaque contrast agent for transvascular use, and the mechanism of action is that after transvascular injection, the blood vessels through which the contrast agent flows will become opaque, so that it can be visualized under X-ray. According to the data of Minenet, at present, 2 imported companies and 3 domestic pharmaceutical companies (including Beite Pharmaceutical) have obtained production approval for iodophorol injection.
Figure 2: Sales of iodophorol injection (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
In China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), the market size of contrast agents will reach 14.8 billion yuan in 2023, a year-on-year increase of 10.72%.
Idophorol injection is the TOP1 product of contrast agent, and the terminal sales of public medical institutions in China will exceed 3 billion yuan in 2023. The market share of the original research company Gaber in France is declining year by year, and it will only be about 4% in 2023, and domestic brands have a lot to offer.
Figure 3: Contrast agents marketed by Chengdu Beite Pharmaceutical and its subsidiaries
Source: Minenet China Listed Drugs (MID) Database
In 2022, Chengdu Beite Pharmaceutical's first contrast agent iopromide injection was approved, and in 2023, the company won iopamol injection and iodixanol injection.
In 2023, in the terminal contrast agent market of China's public medical institutions, iopromide injection is the TOP4 product, iodopamol injection is the TOP7 product, iodixanol injection is the TOP2 product, gadolinium beglumine injection is the TOP16 product, gadobutinate meglumine injection is the TOP9 product, and the approved iodophorol injection is the TOP1 product.
Figure 4: Chengdu Beite Pharmaceutical Co., Ltd. and its subsidiaries reported the production of contrast agents under review
Source: Minenet China Declaration Progress (MED) database
At present, there are two acceptance numbers for iodophorol injection that are under review and approval, and there are also 4 new products (referring to the products that have been declared for the first time) are sprinting. Among them, the current number of competing companies (imported + domestic) of gadolinium terterol injection and iodomepil injection is only 2, and Chengdu Beite Pharmaceutical is expected to strive for the approval of the second domestic one. If the above products are finally approved, the company's contrast agent product matrix will be further expanded.
Source: NMPA official website, Minenet database
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated based on the average retail price of the product at the terminal. The statistics are as of May 13, if there is any omission, please correct!